To investigate the potential effect of TMEM16A on the progression of colorectal cancer, we examined the expression of the most commonly used immunohistochemical markers in the clinical diagnosis of colorectal cancer, including BRAF (V600E), CDX2, EGFR, p53, Ki67, CD34, PMS2, MLH1, MSH6, and MSH2. This evidence concerns the gene MSH2 and colorectal cancer.